BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 19062323)

  • 1. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?
    Hollak CE; Linthorst GE
    Mol Genet Metab; 2009 Jan; 96(1):1-3. PubMed ID: 19062323
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing antibodies to alpha-galactosidase A in Fabry disease.
    Richards SM
    Clin Ther; 2007; 29 Suppl A():S7-8. PubMed ID: 17580240
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
    Linthorst GE; Aerts JM
    J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
    [No Abstract]   [Full Text] [Related]  

  • 4. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease.
    Bénichou B; Goyal S; Sung C; Norfleet AM; O'Brien F
    Mol Genet Metab; 2009 Jan; 96(1):4-12. PubMed ID: 19022694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry.
    Wilcox WR; Linthorst GE; Germain DP; Feldt-Rasmussen U; Waldek S; Richards SM; Beitner-Johnson D; Cizmarik M; Cole JA; Kingma W; Warnock DG
    Mol Genet Metab; 2012 Mar; 105(3):443-9. PubMed ID: 22227322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does enzyme replacement therapy improve symptoms of Fabry disease in patients undergoing dialysis?
    Banikazemi M; Desnick RJ
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):72-3. PubMed ID: 16932395
    [No Abstract]   [Full Text] [Related]  

  • 7. Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.
    Tanaka A; Takeda T; Hoshina T; Fukai K; Yamano T
    J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S249-52. PubMed ID: 20567910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy.
    Ohashi T; Sakuma M; Kitagawa T; Suzuki K; Ishige N; Eto Y
    Mol Genet Metab; 2007 Nov; 92(3):271-3. PubMed ID: 17689998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do we need more intensive enzyme replacement therapy for Anderson-Fabry disease?
    Basic-Jukic N; Kes P; Mokos I; Coric M
    Med Hypotheses; 2009 Apr; 72(4):476-7. PubMed ID: 19124204
    [No Abstract]   [Full Text] [Related]  

  • 10. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
    Wanner C
    Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
    [No Abstract]   [Full Text] [Related]  

  • 11. Enzyme replacement therapy and Fabry kidney disease: quo vadis?
    Warnock DG
    J Am Soc Nephrol; 2007 May; 18(5):1368-70. PubMed ID: 17429046
    [No Abstract]   [Full Text] [Related]  

  • 12. Enzyme replacement in the treatment of Fabry's disease. Is there a point-of-no-return?
    del Toro N; Milán JA; Palma A
    Nephrol Dial Transplant; 2004 Apr; 19(4):1018. PubMed ID: 15031378
    [No Abstract]   [Full Text] [Related]  

  • 13. Fabry disease, enzyme replacement therapy and the significance of antibody responses.
    Deegan PB
    J Inherit Metab Dis; 2012 Mar; 35(2):227-43. PubMed ID: 22037707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
    Martin-Suárez I; Suárez-Marrero C
    Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful desensitization to agalsidase beta after anaphylaxis.
    Talreja N; Butt A; Valle RL; Fox RW; Lockey RF
    Ann Allergy Asthma Immunol; 2014 Jan; 112(1):71-2. PubMed ID: 24331397
    [No Abstract]   [Full Text] [Related]  

  • 16. Anderson-Fabry disease: enzyme replacement therapy.
    Leon-Mateos A; Fernández-Redondo V; Beiras A; Toribio J
    Acta Derm Venereol; 2004; 84(1):88-9. PubMed ID: 15040494
    [No Abstract]   [Full Text] [Related]  

  • 17. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
    Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
    Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
    [No Abstract]   [Full Text] [Related]  

  • 18. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
    Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
    Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting the Development of Anti-Drug Antibodies against Recombinant alpha-Galactosidase A in Male Patients with Classical Fabry Disease.
    van der Veen SJ; Vlietstra WJ; van Dussen L; van Kuilenburg ABP; Dijkgraaf MGW; Lenders M; Brand E; Wanner C; Hughes D; Elliott PM; Hollak CEM; Langeveld M
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32806627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with agalsidase beta during pregnancy in Fabry disease.
    Politei JM
    J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.